T2 Biosystems, Inc. (TTOO)
OTCMKTS
· Delayed Price · Currency is USD
0.190
-0.045 (-19.15%)
Feb 21, 2025, 3:51 PM EST
T2 Biosystems Revenue
T2 Biosystems had revenue of $1.99M in the quarter ending September 30, 2024, with 34.85% growth. This brings the company's revenue in the last twelve months to $7.68M, down -30.19% year-over-year. In the year 2023, T2 Biosystems had annual revenue of $7.19M, down -67.75%.
Revenue (ttm)
7.68M
Revenue Growth
-30.19%
P/S Ratio
0.25
Revenue / Employee
67.94K
Employees
113
Market Cap
3.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7.19M | -15.11M | -67.75% |
| Dec 31, 2022 | 22.31M | -5.75M | -20.50% |
| Dec 31, 2021 | 28.06M | 9.93M | 54.76% |
| Dec 31, 2020 | 18.13M | 9.80M | 117.52% |
| Dec 31, 2019 | 8.34M | -2.16M | -20.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
T2 Biosystems News
- 2 months ago - T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. - GlobeNewsWire
- 2 months ago - T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens - GlobeNewsWire
- 3 months ago - T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 - GlobeNewsWire
- 4 months ago - T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript - Seeking Alpha
- 4 months ago - T2 Biosystems to Host Business Update Call on October 10, 2024 - GlobeNewsWire
- 4 months ago - T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens - GlobeNewsWire
- 5 months ago - T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - GlobeNewsWire